PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6621949

Combination estrogen and progestogen replacement therapy does not adversely affect coagulation.

M Notelovitz·C Kitchens·M Ware·K Hirschberg·L Coone
View original source ↗Export metadata ↓

Abstract

Coagulation and fibrinolysis profiles of naturally menopausal women receiving conjugated estrogens (0.625 or 1.25 mg for 21 of 28 days) and medroxyprogesterone acetate (10 mg for seven of 28 days) for 18 months were compared with those of similar women receiving no hormone therapy. Tests indicative of the dynamics of the coagulation cascade, ongoing intravascular coagulation, and anticoagulation were performed. Hormone therapy had no effect on prothrombin times, activated partial thromboplastin times, or thrombin times. There was no evidence of intravascular coagulation in any of the groups as assessed by platelet counts, fibrinogen antigen and activity, and fibrin degradation products. Antithrombin III antigen and activity, alpha 1-antitrypsin antigen, and alpha 2-macroglobulin antigen, the natural inhibitors of coagulation, were also unaffected by hormone therapy. Plasminogen antigen levels were unaffected, but plasminogen activity was enhanced in the hormone-treated groups, suggesting a stimulatory effect on fibrinolysis. These data indicate that in terms of the coagulation system, healthy women can safely use a combined regimen of conjugated estrogens and medroxyprogesterone acetate.

Explore related subjects

AndrostenedioneAntithrombinsBlood CoagulationEstrogensFemaleFibrinolysisHumansMedroxyprogesteronePlasminogenProthrombin TimeThrombin TimeJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Notelovitz, C Kitchens, M Ware, K Hirschberg, L Coone. 1983. Combination estrogen and progestogen replacement therapy does not adversely affect coagulation.. https://pubmed.ncbi.nlm.nih.gov/6621949/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Enhancing phytosterol tolerance and Repeated-Batch androstenedione production in Mycolicibacterium by modulating global acylation levels.

Global protein lysine acylation, driven by intracellular acyl-coenzyme A (acyl-CoA) accumulation during phytosterol catabolism, has emerged as a potential regulatory mechanism in steroid biotransformation, yet its role in androstenedione (AD) production by Mycolicibacterium remains unexplored. Here, we identified and functionally characterized two antagonistic enzymes in Mycobacterium sp. LZ2 (Msp): MpKat, a GNAT-family acyltransferase catalyzing lysine succinylation, and MpSir, an NAD+-dependent Sirtuin-family deacylase. Genome-wide prediction indicated that 21.56% of lysine residues in the Msp proteome are potential acylation sites, underscoring the broad regulatory impact of this modification. Targeted genetic manipulation revealed that MpSir overexpression increased AD yield by 13.28% (to 83.24%), and MpKat knockout improved yield by 8.86%, while MpKat overexpression decreased yield by 8.69%. Reducing global acylation levels alleviated oxidative stress, elevated NAD+/NADH ratios, enhanced phytosterol tolerance, and improved cell viability. In repeated-batch fermentation, the MpSir-overexpressing strain achieved an average AD yield of 76.5% with a 51% reduction in fermentation time compared to the wild type. This work demonstrates for the first time that modulation of protein acylation via the MpKat/MpSir regulatory axis is a viable and effective strategy to enhance steroid bioconversion in mycobacteria, offering a new dimension for metabolic engineering beyond conventional pathway optimization.

Androstenedione↗
PubMed2007

Fas ligand expression in TM4 Sertoli cells is enhanced by estradiol "in situ" production.

The testis is an immunologically privileged site of the body where Sertoli cells work on to favor local immune tolerance by testicular autoantigens segregation and immunosuppressive factors secretion. Fas/Fas Ligand (FasL) system, expressed prevalently in Sertoli cells, has been considered to be one of the central mechanisms in testis immunological homeostasis. In different cell lines it has been reported that the proapoptotic protein FasL is regulated by 17-beta estradiol (E2). Thus, using as experimental model mouse Sertoli cells TM4, which conserve a large spectrum of functional features present in native Sertoli cells, like aromatase activity, we investigated if estradiol "in situ" production may influence FasL expression. Our results demonstrate that an aromatizable androgen like androst-4-ene-3,17-dione (Delta4) enhanced FasL mRNA, protein content and promoter activity in TM4 cells. The treatment with N(6),2'-O-dibutyryladenosine-3'-5'-cyclic monophosphate [(Bu)(2)cAMP] (simulating FSH action), that is well known to stimulate aromatase activity in Sertoli cells, amplified Delta4 induced FasL expression. Functional studies of mutagenesis, electrophoretic mobility shift (EMSA) and chromatin immunoprecipitation (ChIP) assays revealed that the Sp-1 motif on FasL promoter was required for E2 enhanced FasL expression in TM4 cells. These data let us to recruit FasL among those genes whose expression is up-regulated by E2 through a direct interaction of ERalpha with Sp-1 protein. Finally, evidence that an aromatizable androgen is able to increase FasL expression suggests that E2 production by aromatase activity may contribute to maintain the immunoprivilege status of Sertoli cells.

Androstenedione↗
PubMed2006

The celiac ganglion modulates LH-induced inhibition of androstenedione release in late pregnant rat ovaries.

BACKGROUND: Although the control of ovarian production of steroid hormones is mainly of endocrine nature, there is increasing evidence that the nervous system also influences ovarian steroidogenic output. The purpose of this work was to study whether the celiac ganglion modulates, via the superior ovarian nerve, the anti-steroidogenic effect of LH in the rat ovary. Using mid- and late-pregnant rats, we set up to study: 1) the influence of the noradrenergic stimulation of the celiac ganglion on the ovarian production of the luteotropic hormone androstenedione; 2) the modulatory effect of noradrenaline at the celiac ganglion on the anti-steroidogenic effect of LH in the ovary; and 3) the involvement of catecholaminergic neurotransmitters released in the ovary upon the combination of noradrenergic stimulation of the celiac ganglion and LH treatment of the ovary. METHODS: The ex vivo celiac ganglion-superior ovarian nerve-ovary integrated system was used. This model allows studying in vitro how direct neural connections from the celiac ganglion regulate ovarian steroidogenic output. The system was incubated in buffer solution with the ganglion and the ovary located in different compartments and linked by the superior ovarian nerve. Three experiments were designed with the addition of: 1) noradrenaline in the ganglion compartment; 2) LH in the ovarian compartment; and 3) noradrenaline and LH in the ganglion and ovarian compartments, respectively. Rats of 15, 19, 20 and 21 days of pregnancy were used, and, as an end point, the concentration of the luteotropic hormone androstenedione was measured in the ovarian compartment by RIA at various times of incubation. For some of the experimental paradigms the concentration of various catecholamines (dihydroxyphenylalanine, dopamine, noradrenaline and adrenaline) was also measured in the ovarian compartment by HPLC. RESULTS: The most relevant result concerning the action of noradrenaline in the celiac ganglion was found on day 21 of pregnancy resulting in the inhibition of androstenedione release from the ovarian compartment. In addition on day 15 of pregnancy, LH placed in the ovarian compartment led to an inhibition of the release of androstenedione, and this inhibitory effect was further reinforced by the joint action of noradrenaline in the celiac ganglion and LH in the ovary. The levels of catecholamines in the ovarian compartment showed differences among the experiments; of significance, the joint treatment of noradrenaline in the celiac ganglion and LH in the ovary resulted in a remarkable increase in the ovarian levels of noradrenaline and adrenaline when compared to the effect achieved by either one of the compounds added alone. CONCLUSION: Our results demonstrate that the noradrenergic stimulation of the celiac ganglion reinforces the LH-induced inhibition of androstenedione production by the ovary of late pregnant rats, and that this effect is associated with marked changes in the release of catecholamines in the ovary.

Androstenedione↗